Kimberly-Clark and Hormel are attractively valued Dividend Aristocrats with strong balance sheets and yields above 5%. KMB demonstrates volume-led growth, and industry-leading productivity and expects generational value from the Kenvue integration, despite near-term oil price headwinds. HRL is pivoting toward higher-margin branded proteins, divesting low-margin businesses, and projecting 7% EPS growth at the midpoint for 2026.
Stanley Black & Decker remains a "Buy," trading at a low-teens P/E and offering a high dividend yield with improving fundamentals. Q1 2026 results beat expectations: $0.80 EPS vs. $0.59 consensus, $3.85B revenue, and strong capital allocation via $1.6 billion CAM divestiture. SWK targets gross margin expansion to 34%–35% in 2H, expects leverage to drop to ~2.5x, and plans shareholder returns through buybacks.
Warren Buffett stepped down as chief executive of Berkshire Hathaway (NYSE: BRK-B | BRK-B Price Prediction) on December 31, 2025, after six decades leading the conglomerate he transformed from a struggling textile mill into a $1 trillion empire.
It's not often that a 141-year-old company has the opportunity to generate excitement. But after AT&T NYSE: T reported Q1 2026 earnings on April 22, that is exactly how the market has been reacting.
ProShares S&P 500 Dividend Aristocrats ETF (NYSEARCA:NOBL) applies the most demanding standard of the three funds.
After reaching an all-time high of $179.10 in November 2021, Nike closed at $44.20 as of April 14th, which is equivalent to a ~75% decline in less than five years. The entrenched pessimism surrounding Nike's turnaround story is perfectly understandable, as the stock is currently trading at a price level last seen in October 2014, or almost 12 years ago. Apple's CEO Tim Cook and Nike's CEO Elliot Hill both purchased a noteworthy amount of shares on the open market over the last few days, signalling confidence around the turnaround plans.
Market volatility has rattled portfolios in 2026, with broad indexes pulling back as slowing growth weigh on sentiment.
Abbott Laboratories has declined over 16% since my last review, which was previously rated a HOLD, as the valuation was a little rich. The acquisition of Exact Sciences adds a solid piece to a company with a long, proven track record. The segments were kind of a mixed bag in the most recent earnings report, and I'll be monitoring the struggling areas to see where they might go.
Nike (NYSE: NKE) just delivered its latest quarterly dividend of $0.41 per share, paid on April 1, 2026, marking 24 consecutive years of dividend increases.
Realty Income is a core income buy in my portfolio. The net lease REIT's massive total addressable market allowed it to source a record $121 billion in 2025. Realty Income heads into 2026 with over $4 billion of dry powder on its balance sheet.
Union Pacific is just six years away from becoming a Dividend Aristocrat. The railroad operator is benefiting from nearshoring trends and improved operational efficiency, with the pending Norfolk Southern merger serving as additional growth fuel. Union Pacific's adjusted debt-to-EBITDA ratio closed out 2025 at 2.7x, which was in line with 2024.
Dividend Aristocrats, tracked via NOBL, outperformed SPY YTD despite a sharp March pullback, with 44 Aristocrats beating SPY and 17 posting double-digit gains. Momentum, valuation (via dividend yield theory), and projected long-term total return now guide Aristocrat selection, with 39 currently screening as undervalued and offering ≥10% expected annualized returns. Recent dividend increases from CL, GD, LIN, and O bring the 2026 average Aristocrat dividend growth rate to 3.40%, with Realty Income expected to announce further hikes throughout the year.